Key Highlights

  • Arch Capital (NASDAQ:ACGL) is at USD 109.31, up 2.77%, on 2.15 million shares (relative Volume 1.00), with a USD 37.30 billion market cap, a 52-week high of USD 110.26, a P/E of 8.93 and EPS of USD 12.24 on the 52-week high screen, captured November 4, 2026.
  • Arthur J. Gallagher (NYSE:AJG) trades at USD 278.89, USD 2.64 under its 52-week high of USD 281.53, with Revenue up 18%.
  • ACCO Brands (NYSE:ACCO) is at USD 5.46, down 0.73%, on 3.87 million shares (relative volume 3.15), with a USD 504.00 million market cap, a 52-week high of USD 5.84, a P/E of 7.83 and a 5.45% Dividend Yield on the 52-week high screen, captured November 4, 2026.
  • Amneal Pharmaceuticals (NASDAQ:AMRX) is at USD 20.44, down 4.97%, on 5.02 million shares (relative volume 1.17), with a USD 7.12 billion market cap, a 52-week high of USD 21.68, a P/E of 42.65 and EPS growth of 7,387.50% on the 52-week high screen, captured November 4, 2026.

1. Arch Capital (NASDAQ:ACGL)

Arch Capital (NASDAQ:ACGL) trades at USD 109.31, USD 0.95 under its 52-week high of USD 110.26, while premiums declined 3.0%. Shares near highs meet no resistance from earlier holders, yet there is less buffer for a soft report, which applies to ACGL. Third quarter results on October 27, 2026 showed Net Income available to common of USD 1,025 million, or USD 3.00 per diluted share, and after-tax Operating Income of USD 910 million, or USD 2.67 per share, compared with USD 2.77 a year earlier. Net premiums written dropped 3.0% to USD 3,845 million, and the combined ratio rose to 82.5% from 79.8%. Arch bought back USD 1.4 billion of stock, and Book Value per share was USD 67.90, so the USD 109.31 quote equals about 1.61 times book by simple math. The concern is that premium volume and per-share operating income declined while the shares rose, and a rising combined ratio shrinks Underwriting margins.

2. Arthur J. Gallagher (NYSE:AJG)

On the 52-week high screen, Arthur J. Gallagher (NYSE:AJG) is at USD 278.89, up 1.02%, on 2.80 million shares (relative volume 1.47), with a USD 71.48 billion market cap, a 52-week high of USD 281.53, a P/E of 42.60 and a 1.00% dividend yield, captured November 4, 2026. A peak shows the price level, not the value, so the results and valuation behind AJG call for a closer look. The company acquired The Mund Group on October 21, 2026 and a Melbourne firm on October 19, 2026, while Pen Underwriting bought Ornella Underwriting of Ireland on October 7, 2026; terms were not disclosed. The screen shows a P/E of 42.60 and EPS of USD 6.55. Third quarter 2026 results came out October 29, 2026, and published coverage of the call reports revenue growth of 18%, organic growth of 5%, and a 25% rise in net Earnings and adjusted EBITDAC, all single source figures. The concern is a P/E of 42.60 after a 46% climb from the low, undisclosed deal terms, and growth figures from one source.

3. ACCO Brands (NYSE:ACCO)

ACCO shares sit at USD 5.46, USD 0.38 below the 52-week peak of USD 5.84, and Tariff refunds helped push adjusted EPS higher. A peak says where the price sits, not whether it is cheap, so the results and valuation behind ACCO are worth checking. Adjusted EPS was USD 0.28, up from USD 0.21, including USD 0.11 per share from net tariff refunds. Full-year adjusted EPS guidance sits between USD 0.98 and USD 1.02, with USD 0.12 of refunds included. The concern is that sales are declining, comparable sales dropped 6.2%, and refunds lifting adjusted EPS will not recur.

4. Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals (NASDAQ:AMRX) fell 4.97% to USD 20.44 after touching a 52-week high of USD 21.68, despite raising its 2026 guidance. Shares at peaks meet no resistance from earlier holders, but there is less room for error if results slow, which applies to AMRX. On a GAAP basis Amneal lost USD 22 million, or USD 0.06 per share, versus net income of USD 2 million a year earlier, citing one-off costs linked to the Kashiv Acquisition and a higher tax charge. The company lifted 2026 net revenue guidance to USD 3.15 billion to USD 3.25 billion and adjusted EPS guidance to USD 1.04 to USD 1.08. The worry is a GAAP loss and a weaker Cash Flow outlook arriving with higher revenue guidance, while the reason for the 4.97% fall is unconfirmed.

5. Addus HomeCare (NASDAQ:ADUS)

On the 52-week high screen, Addus HomeCare (NASDAQ:ADUS) is at USD 125.75, up 0.17%, on 508,400 shares (relative volume 2.34), with a USD 2.35 billion market cap, a 52-week high of USD 127.06, a P/E of 22.06 and EPS of USD 5.70, captured November 4, 2026. A peak reveals where a price stands, not whether it is inexpensive, so the release and valuation need a look. Adjusted EPS came in at USD 1.83, up 17.3% from USD 1.56, and adjusted EBITDA was USD 51.2 million, up 13.5%. No updated guidance accompanied the release. The worry is the AccentCare deal awaiting regulators, the lack of guidance, and a prior analyst downgrade.

Where Things Stand

Valuation varies widely. ACCO at 7.83 and ACGL at 8.93 look cheap on trailing earnings but carry tariff refunds and falling premiums, ADUS at 22.06 has a pending deal, and AJG at 42.60 and AMRX at 42.65 price in growth, so a high P/E raises the bar for results. Highs often come with strong results, yet screens also catch one-time boosts such as special dividends, tariff refunds and recent listings. Checking what can repeat separates durable strength from a single event. Readers comparing these names should keep the screen date and the filing date apart, since the two can fall on different days.